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Optimal Supply Chain Structure for Distributing Essential Drugs in Low Income Countries: 
Results from a Randomized Experiment 
 
Abstract 
Despite increased investments in health commodity procurement, the availability of essential medicines at 
health facilities remains very low in many low and middle income countries. The lack of a well-
functioning supply chain for essential medicines is often the cause of this poor availability. Using a 
randomized experiment conducted in over 400 health facilities and 24 districts in Zambia, this study helps 
understand the optimal supply chain structure for essential medicines distribution in the public sector in 
low income countries. It focuses on the availability of 15 essential medicines at the health facility level 
and compares between a cross-dock based two-tier distribution network and a three-tier network. The 
study shows that a two-tier “cross- dock” like system outperforms a traditional three-tier drug distribution 
system due to better information flow and better management accountability even though stock is 
positioned closer to the health facilities in the three-tier system. Results from the study advance existing 
knowledge in the area of public sector distribution system design in general and drug distribution systems 
in developing countries in particular. 
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Introduction 
 
The availability of essential medicines is a persistent challenge in developing countries. A third of the 
world’s population, including almost half of the population on the African continent, lacks systematic 
access to essential drugs (WHO, 2004). The health consequences from such low levels of availability are 
pronounced (Yadav, 2010).  
 
Access to essential drugs is contingent upon well-functioning supply chain systems that move drugs from 
the manufacturer through to end use. Supply chain management in public sector health systems has 
received increasing attention in recent years—as both a priority and a challenge for many countries—as 
governments struggle to deliver an increasing number of products (JSI, 2010). With the last decade’s 
increases in financing for health1 and with much of this new funding earmarked for combating priority 
diseases and less for health system strengthening, many public supply chains are now in charge of 
delivering a larger number and volume of products, yet are given limited additional resources for 
investments in supply chain improvements. Despite the increasing awareness about the importance of 
efficient logistics systems for attainment of health outcomes, systematic analysis of essential drugs 
distribution system and their impact on stock-out rates at the point of service delivery and priority health 
outcomes remains limited.  
 
This paper investigates how to optimally structure public sector supply chains through an examination of 
three contrasting supply chain distribution models. A randomized evaluation framework is used to 
examine the effectiveness of the three supply chain structures, including cross-docking, a supply chain 
structure where warehouses function as inventory coordination points rather than inventory storage 
points. The study was conducted in Zambia and is the first large scale study using an experimental 
evaluation framework to understand how to structure the public sector supply chain for distribution of 
essential medicines in low income countries. 
 
Background 
 
The structure of the distribution network that is used to transport a product from the manufacturer to end 
consumers influences both the product availability to the end consumer and the cost of operating the 
distribution network (Simchi-Levi et al., 2003, Chopra Miendl 2007). In the field of operations and 
supply chain management, disciplines which form the operational basis for the interventions studied in 
this paper, a large body of literature explores the role of supply chain structure. Researchers study both 
the optimal number of tiers in the distribution network as well as the operating and control rules used at 
each tier.  
 
For the typical health system, a single central warehouse cannot effectively supply to all the health 
facilities and thus it is necessary to have a tiered distribution network, with several storage and 
distribution levels. The optimal number of levels in a distribution system is dependent on geographical 
factors, demand at each health facility, frequency of shipment, storage space availability, and transport 
                                                          
1 Health aid increased from USD 5 billion in 1990 31.3 billion in 2013 and a large share of this increase was through 
disease-specific funding from Global Health Initiative such as the Global Fund to fight AIDS TB and Malaria (GFATM) 
and the Vaccine Alliance GAVI (IHME, 2013). 
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cost structure (Ballou, 1998; Chopra Miendl 2007, Simchi-Levi et al., 2003). Many developing countries, 
including Zambia, typically have three tiers in their public sector distribution system; where the central 
warehouse supplies to the district warehouses which in turn send supplies to the health facilities. Two and 
four tier models are also used in some countries (Yadav, Tata and Babaley 2011). 
 
The complexity of managing inventory increases with the number of tiers/locations where inventory 
resides. Empirically, for most commercial settings, the number of tiers in the distribution channel has 
been growing smaller in recent years (Fletcher and Wehlage 2008). Many businesses that used to have a 
three-tier structure earlier now have a two-tier structure and some of those with a two-tier structure are 
now trying to manage with a single tier channel. Increased number of tiers in the supply chain greatly 
reduces supply chain visibility,  i.e. the ability of planners at the higher tiers to make decisions based on 
actual demand. It also makes each tier dependent on the operational performance of tiers that are 
upstream or downstream from it, thereby creating managerial accountability problems in the supply chain. 
For businesses that have a larger number of tiers, initiatives such as cross-docking2 and Vendor-Managed 
Inventory (Simchi-Levi, et al., 2003) are increasingly becoming popular. Snyder (1995) outlines the case 
of Walmart where significant savings in transportation, inventory, and stock-out costs were achieved after 
changing their distribution system to two-tier and implementing cross-docking. Cross-docking is a 
process in which a warehouse function as inventory coordination point rather than inventory storage point 
(Simchi-Levi et al., 2003). In typical cross-docking systems, goods arrive at a warehouse from the 
previous tier and are delivered to the next tier as rapidly as possible without any “lay away” inventory.  
 
With cross-docking, frequent deliveries are viable to a larger number of distribution points without a 
concomitant increase in transportation cost (Gue 2007). However, cross-docking does not always result in 
gains – Waller et al. (2006) show that when centralized information about the level of inventory and 
demand at each stage is not available, cross-docking may require more total inventory in the system to 
avoid stock-outs.  Zinn and Bowersox (1988) caution that as firms implement cross-docking, they must 
pay careful attention to the impact of cross-docking on product availability to end-consumers. Given that 
the impact of cross-docking requires understanding of many context specific variables, it is unclear how 
well it performs in a public sector supply chain for essential medicines. This paper presents the first 
rigorous study that addresses this issue. 
 
A parallel question to the issue of number of tiers in the distribution system concerns the operating 
/control rules that should be used to decide inventory levels at each tier in the system. A push system (an 
allocation system), a pull (a requisition system) or a combination, are most commonly used because both 
push and pull system of distribution have their own advantages and disadvantages (Yadav, Tata and 
Babaley 2011). To address this question, the seminal work by Clark and Scarf (1960) considers a serial 
multi-tiered inventory system and determines the optimal inventory control policy by taking the 
perspective of the central planner, who has access to the status of the inventories at all sites and makes all 
stocking decisions for the entire system. Since then many scholars have studied these problems and have 
emphasized the need of better information integration between the tiers in the distribution system. A 
notable example is Lee and Whang (1999) who show that incentive problems may arise in multi-tiered 
distribution systems when decisions are delegated to decentralized sites that have intimate knowledge of 
                                                          
2 Cross docking is a distribution system where items received at the warehouse are not received into stock, but are 
prepared for shipment to another location or for retail stores. 
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their immediate surroundings. Decentralization of stocking decisions can lead to potential incentive 
misalignment between the “principal” (the central planner) and “agents” (the decentralized site managers) 
as each site is maximizing its own performance metric. Bossert et al. (2006) studies the impact of 
decentralization on logistics systems in two developing countries, Ghana and Guatemala, and finds that 
centralized systems may result in better performance in the area of inventory control and information 
systems, while decentralization may result in better planning and budgeting. They conclude that logistics 
systems can be effectively decentralized for some functions while others should remain centralized.  
 
In the public health literature, a few studies have looked into factors that cause stock outs of essential 
products at the point of service delivery. Quick (2003) identified the following reasons for stock outs: 
insufficient funding to procure the needed quantities, inaccurate forecasts, long and complex procurement 
processes, and unreliable transportation. The performance of the in-country distribution system in the last 
tier as well as delivering to remote areas is also noted to be a key bottleneck to ensuring higher 
availability of public health products at health facilities (Yadav 2010). Similarly, an assessment of the 
distribution system for essential drugs in Zambia (Beer, 2007) showed that although the central to district 
distribution had recently improved; the district to health facility distribution had bottlenecks resulting in 
stock-outs. Antimalarial medicine diversion has also been reported across numerous African markets and 
can lead to serious stock-outs in the public sector (Bate et al 2010). Inadequate human resource capacity 
including the inability to select, quantify and distribute medicines, and irrational prescribing and 
dispensing have also been identified as reasons for stockouts of certain drugs (Waako et al 2009). 
 
There are few studies to date that rigorously measure the impact of interventions addressing supply chain 
improvements. Seiter (2010) provides a review of various procurement and financing related 
interventions that help improve the pharmaceutical supply system in developing countries. Apart from 
procurement and financing, training has been documented as the main intervention to improve 
pharmaceutical availability in public sector drug supply chains (Matowe et al 2008) but there is no clear 
evidence that training achieves greater availability of drugs at the health facility level. Conn et al (1996) 
describe the impact of a project to strengthen the basic management skills of district-level health teams in 
two out of the three health regions of the Gambia and find that it only leads to moderate improvements in 
health services delivery.3  
 
The Pharmaceutical Supply Chain and Health in Zambia 
 
With a GNI per capita, PPP (current international $)of approximately $3810 in 2013 Zambia has grown 
steadily over the past decade but this has not translated into significant poverty reduction. Forty two  
percent of the population live in extreme poverty and the absolute number of poor has increased from 
about 6 million in 1991 to 7.9 million in 2010, primarily due to population growth (World Bank, 2015). 
Providing basic health services and essential medicines to most of the population remains a challenge. 
The Zambian Ministry of Health (MOH) and its cooperating partners have invested substantial amounts 
                                                          
3 Additional work includes the Zimbabwean Ministry of Health and Child Welfare (MOHCW), who conducted a 
pilot project to improve delivery of TB and malaria drugs to public health facilities using a new distribution system 
operating rule called the Zimbabwe Informed Push (ZIP) system. The results of this study are still to be published. 
Another study in Kenya (Raja et al 2008) looks at the strategic redesign of the public health distribution network 
using a simulation experiment. 
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of money in the public sector  drugprocurement and distribution system in recent years. Despite these 
efforts, health centers across Zambia continue to face difficulties accessing drugs and medical supplies in 
appropriate quantities. The nationally representative 2006 Public Expenditure Tracking Survey (Picazo, 
and Zhao (2008)) concluded that essential and life-saving drugs were widely unavailable in health 
facilities across the country. For example, ampicillin, an antibiotic, was out of stock in 86 percent of the 
urban health clinics for an average duration of 7.4 weeks. 
 
A priority for the Zambia health sector is malaria control. Over the last five years, the National Malaria 
Program has made great improvements in indicators for malaria prevention (Chizema-Kawesha et al, 
2010). However, malaria case management indicators, which rely on drugs being available at the point of 
service delivery, continued to lag behind. Artemether-Lumefantrine, the first line treatment for malaria, 
was out of stock in 44 percent of the rural health facilities for an average duration as long as 9.5 weeks. 
According to the results from the 2008 Malaria Indicator Survey (MIS)4, only 43 percent of children 
under the age of five took an antimalarial within 24 hours of onset of symptom. Of these, no more than 
16.6 percent of children living in urban area and 11.5 percent of those in rural areas took Artemisinin-
based combination therapy (ACT), the adopted first line treatment for malaria.5  
 
With regard to the existent supply chain structure, Zambia has a three-tier public sector distribution 
system of essential drugs. Primary distribution of drugs and other health commodities from Lusaka to 
approximately 120 districts stores and hospitals is managed by a parastatal agency called Medical Stores 
Limited (MSL). Secondary distribution of commodities from district stores to approximately 1500 health 
facilities falls under the responsibility of District Health Management Teams (DHMTs) reporting to the 
MOH. Various assessments, conducted prior to the design of this Essential Drugs Public Pilot Program 
(EDPPP), identified secondary distribution, from district stores to health facilities, as the main bottleneck 
in the distribution system (Beer, 2007, Picazo, and Zhao2008 and Yadav 2007). This finding was also 
confirmed in the baseline data for this project which revealed significantly higher stock-out rates of 
essential drugs in health facilities compared to the district stores and hospitals; thirteen of the fifteen 
essential drugs that were tracked in the baseline survey experienced a higher probability of stock-out at 
the health facility level rather than at the district store. The majority of these differences are statistically 
significant at conventional levels.  
 
Secondary distribution is particularly challenging in Zambia because health clinics are geographically 
dispersed, off-road vehicles are often necessary to reach health facilities due to difficult roads, and certain 
areas are inaccessible during the rainy season. In the system that existed before EDPPP, health facilities 
estimated their needs for drugs (apart from antiretroviral (ARV) drugs and those drugs that were a part of 
the Primary Health Center Kit) and sent their requisitions to the District Health Office.6 Often the lack of 
                                                          
4 MIS 2010 Results: Thirty-four percent of febrile children took an antimalarial medicine in 2010, compared to 43% 
in 2008; the percentage of febrile children who took Coartem® treatment, more than doubled from 12% in 2008 to 
26% in 2010. 
5 Results were similar in the 2006 Malaria Indicator Survey (MIS), where only 37 percent of children under the age 
of took an antimalarial within 24 hours of a fever. 
6 An additional 52 items including 20 basic medicines were delivered to the health centers in the PHC kits. Health 
facilities were allocated a specific number of kits each month depending on their size, service area, and past use. 
Consumption data on items in the kit or drugs ordered separately was not collected by the drug monitoring data 
system. 
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any communication means between the health facility and the district implied that the health facility staff 
would travel to the district along with their requisitions and “pick up” stock. Additional challenges also 
include lack of dedicated logistics staff at the district level and lack of working communication 
technologies. 
 
Several field studies were carried out between 2006 and 2008 to assess the bottlenecks in the public sector 
essential medicines distribution system in Zambia. The main reasons for the elevated stock-outs of 
essential medicines at the health facilities captured in those studies are summarized below:  
 
• Secondary distribution from the District Central Store to health centers was not carried out in a 
uniform manner across the country and many health centers were required to travel to their 
district headquarters to pick up items that were not included in the health facility kits.  
• Communication between the District Central Store and health centers was difficult and relied 
upon a high-frequency radio system and personal cell phones.  
• Lack of demand data resulted in the fact that supply decisions down to district level did not take 
actual consumption patterns into account.  
• Transport was a significant bottleneck in the secondary distribution system. There are insufficient 
vehicles available at the district level to complete all necessary tasks of the District Central Store 
officer, and those that existed broke down regularly because of poor roads and high usage. Some 
health centers were routinely cut off for months due to poor accessibility and seasonal weather 
patterns. 
 
Based on these observations, the strengths and weaknesses of a number of potential different distribution 
models were assessed by the MOH with donor support.7 Considered models included direct distribution 
to health facilities, distribution through regional medical stores, contracting distribution/transport 
functions to private third party companies and enhancing planning capacity at various levels in the 
distribution system. The nature of the road network and the vehicle fleet at MSL rendered some options 
such as direct distribution to health facilities infeasible. Similarly, third party transport companies in 
Zambia did not have coverage in remote and rural parts of the country making the contracting out option 
challenging for national scale-up.  Extensive consultations were conducted and an emergent consensus 
centered on two proposed alternative models that would be contrasted with the existing system through a 
prospective randomized evaluation design.  
 
Program and Intervention Design: The supply chain interventions 
 
In April 2009, the EDPPP program was launched. The objective of the program was to identify a cost-
effective way to improve the availability of drugs through strengthening of the supply chain from MSL to 
districts and health facilities. The EDPPP adopted a prospective evaluation design to assess the 
effectiveness of three distribution models (two alternative models, model A and model B, and the current 
system), which were chosen on the grounds of potential cost-effectiveness and technical feasibility as 
described above. The interventions were implemented over a 12 month period.  
 
                                                          
7 Donors actively involved in these deliberations included USAID, JSI, Crown Agents, DfID, and the World Bank. 
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In Model A the health facilities order drugs from the district and the district store maintains the stock of 
drugs i.e. the district store remains a stock holding point, hence Model A remains a three-tier system. A 
new role called the Commodity Planner (CP) is introduced at the district level to enhance stock planning 
capacity. This CP is responsible for coordinating orders from the health facilities and stock management 
at the district. The CP also ensures that requisition requests are sent every month by each health facility to 
the district store and performs picking and packing operations at the district level to fulfill the order 
requisitions of health facilities under that district. The CP estimates the overall requirements and places 
orders to central stores (MSL) for the stock needed to maintain the desired inventory level at the district 
store.8 The CPs were trained on basic principles of inventory and stock management.  
 
 Model B eliminates the intermediate storage of drugs at the district level. The district store is converted 
into a “cross-dock”, i.e. point of transit, wherein it receives shipments from MSL that are pre-packed for 
individual health facilities. Under this option, the district does not carry any stock or perform any 
secondary picking and packing and the supply chain becomes a two-tiered system. Order requisitions 
from the health facilities are directly transmitted to MSL on a monthly basis where assembling and 
sealing of packages to individual health facilities takes place. As in Model A, a commodity planner (CP) 
is added to the district store under this option but her role is limited to ensuring the delivery of the 
packages to the health facilities as well as facilitating the order information from the health facilities to 
MSL.  
 
Both models A and B share common features which include drugs included in the system as full supply 
products, health Center Kits disaggregated into individual drugs at the central level and District Health 
Office (DHO)/facility orders are augmented by bulk stock available at MSL. Table 1 summarizes the 
detailed features of the three delivery models.  
 
Evaluation Design and Data 
 
To measure the comparative effectiveness of each models A and B both vis-à-vis the control and with 
each other, the pilot was accompanied by a prospective cluster randomized evaluation design, with 
randomization of delivery models conducted at the level of the district. This relatively aggregate level of 
randomization is natural given the key role of the district structure, including the responsibilities of the 
district based CP. Randomized assignment below the district (i.e. the health facility), even if feasible from 
a systems perspective, would likely be subject to spillovers due to the common presence of a recently 
trained CP as well the general coordinating role of the DHO; therefore randomized exposure at the facility 
level was not pursued. 
 
Randomization at the district level does come with potential inferential cost in the power of the analysis 
as the number of units of randomization is limited. In the case of the EDPPP, Models A and B were each 
piloted in eight districts around the country, and data was also collected from eight control districts. 
Besides the challenge to inferential power by the relatively few number of study units, traditional 
                                                          
8 Existing pharmacy technologists carried out the CP role in districts where there was a pharmacy technologist; 
while new CPs were, hired directly under MSL, in districts were the pharmacy technologist position was vacant. For 
the 16 intervention districts, there were 12 CPs recruited and the remaining 4 districts relied on the existing 
pharmacy technologists.  
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approaches to standard error estimates, notably the cluster-robust standard error, may be downward 
biased and thus over-reject the null hypothesis of no treatment effect (Cameron et al., 2008). To 
counteract this potential bias, the precision of statistical tests will be assessed through Randomization 
Inference (RI) which assumes all observed outcomes and covariates to be fixed and generates the 
reference distribution of test statistics by modeling the treatment assignation as the sole random variable 
in the data (Ernst, 2005). RI compares the actual test statistic observed in the evaluation against the 
distribution of all conceivable test statistics as determined through permutation methods – where the 
actual statistic falls in this distribution determines the exact p-value. This one-tailed hypothesis test is 
considered an exact test because it does not require a large-sample approximation as randomization itself 
is the basis for inference and permutation methods have exhausted all possible treatment assignations 
across districts. An exact test has the added benefit that it does not impose distributional assumptions that 
are often behind approximations of reference distributions in standard hypothesis testing. 
 
The stratified random assignation of models A and B guarantees in expectation the internal validity of any 
causal estimate. Researchers and policy makers also care about the generalizability of any impact estimate 
to the wider national context; therefore study districts were stratified and purposively selected to test the 
models in a variety of settings thereby increasing the study’s external validity. Districts were first 
stratified by rural or peri-urban status as well as by region to ensure a geographic balance in the selected 
districts and to further control for possible region wide influences on stock availability such as weather 
patterns.9 Within these four strata, districts were assessed on risk factors for Artemether-Lumefantrine 
(AL – one of the primary tracer drugs) stock outages and then stratified into low risk (those with 2 or 
fewer risk factors) or high risk districts (those with 3 or 4 these risk factors). These risk factors included 
high malaria incidence (a positive relationship – the greater the malaria incidence the more likely a 
reported AL stock outage), likelihood of phone at facility level (a negative relationship), total district 
population (negative relationship), and average catchment area of facility (positive relationship). Together 
these predictors accounted for approximately 15 percent of the variation in observed AL outages in the 
universe of districts. 
 
Within each of these eight strata, one district was randomly assigned to receive Model A, one to Model B, 
and one to the control group. The location of each selected district is shown in Figure 1. The 24 study 
districts comprise one-third of Zambia’s 72 districts and study activities are represented in every region of 
the country. 
 
The primary goals of the supply-chain intervention are to maintain stocking levels of key medicines and 
reduce both the incidence and duration of pharmaceutical stock outs. As such the primary metrics of 
program performance will include the incidence of drug stock-over at the time of survey as well as the 
inventory count of each drug. These metrics will be assessed for 15 tracer drugs deemed critical to the 
conduct of preventive and curative primary care in the Zambian context. Given the primacy of malaria in 
many rural areas of Zambia, four variants of the malaria curative drug AL, applicable to four non-
overlapping age ranges, are included in the tracer list as are other malaria related drugs such as malaria 
Rapid Diagnostic Tests (RDTs) and Sulfa-Pyramethamine (SP), a malaria preventive. Additional tracer 
drugs include two types of anti-biotics, a deworming medicine, and several types of contraceptives. 
                                                          
9 The relatively small number of urban districts, as well as the relatively good performance of pharmaceutical supply 
chains in those districts, led to their exclusion from the program. 
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Besides inventory and stock-out incidence, other impact measures assessed include the duration of stock-
outs and the condition of the primary health clinic storage facility. 
 
Two dedicated facility surveys, qualitative interviews with Commodity Planners, and an analysis of 
facility stockcards provided data to evaluate the program. The baseline data collection, covering 416 
health centers, 23 hospitals and 18 District Health Offices, and was conducted in Dec-Jan of 2008/09 
prior to start of the pilot in April 2009.10 The follow up data collection was conducted during the same 
months in 2009/10, one year after the baseline survey and 9-10 months after the start of the pilot program. 
Data on inventory and stock-out rates of the fifteen tracer drugs were collected at both baseline and end-
line. The end-line survey was more comprehensive in design and included supplementary information on 
stocking history and storage conditions.  
 
Although the selection of districts followed stratified random sampling and hence districts are balanced 
across rural and peri-urban areas as well as region, the data allows a check of balance of key stock 
measures at baseline. Tables 2 and 3 report the mean stock-out probability and inventory count of the 15 
tracer drugs, respectively, at the time of baseline interview for all facilities surveyed in the 24 districts in 
the study. Each table reports the means separately for the A, B, and control groups as well as the exact p-
value of the difference tests between all pair-wise comparisons of A, B, and control. Pairwise 
comparisons significantly different from each other at the 10% level are indicated in bold. 
 
For the vast majority of pair-wise comparisons with the control districts, the baseline facility outcomes in 
A or B districts are not significantly different. In fact only one of the stock-out rates across the 15 drugs 
observed in Model A districts is significantly different from that found in the control district facilities. In 
the Model B district facilities, none of the stock-out rates are significantly different from control district 
facilities and only two are different from those in Model A districts. In terms of the inventory count for 
the same 15 drugs, in only one pair-wise comparison (a Model A versus Control district) is the stock level 
significantly different.  The stratified randomization process appears to have been highly successful in 
balancing key outcomes at baseline and thus ensuring suitable comparability between treatment and 
control districts.  
 
Results 
 
The summary results from the pilot program evaluation show that availability of essential drugs improved 
remarkably at the health facility level, particularly in districts where Model B was implemented. Figures 1 
and 2 show the changes in drug availability of the pilot program for select tracer drugs both pre- and post-
pilot implementation in A and B districts respectively. Taking one example from Model A, during the 
baseline period 38 percent of health facilities were stocked out of DepoProvera, while the stock out rate in 
the follow up period was reduced to 17 percent. Reductions in the probability of stock out rates in the 
same magnitude are observed for Amoxicillin and ACT for adults. Although the reductions in stock out 
rates in model A districts is apparent, the gains are far less than the gains observed in model B districts. 
Figure 2 shows dramatic decreases in stock out rates for the same select drugs; with decreases in stock out 
                                                          
10 Health centers, health posts that carry pharmaceutical stock, as well as district hospitals were all included in the 
data collection efforts. Since the primary goal of the interventions considered is to improve drug availability at the 
primary clinic level, most of the analysis will focus on primary health clinics and health posts. 
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rates larger than 40 percentage points for SP, DepoProvera, Amoxicillin and AL for adults. Overall these 
results show large performance improvements in the supply chain in model B districts whereas the A 
districts perform somewhat better with respect to baseline stock-out rates.  
 
While the information presented in Figures 1 and 2 is suggestive, more formal tests of differential gains 
between intervention and control districts are presented in Tables 4 and 5. This analytic framework takes 
into account the relative difference between baseline and endline values in both the treatment and control 
areas through a difference-in-difference regression specification. This specification, given in equation (1) 
below, relates the outcome of interest (for a particular tracer drug), O, at facility f in district d at both 
baseline (t=0) and follow-up periods (t=1). The variables A and B are binary indicators for A and B 
districts, respectively. T is a binary indicator for the follow-up period (t=1). 
 
(1) 
 
The analysis also controls for the district-level stratification variables, X. The coefficients of interest, 
those that identify the causal impact of Models A and B through the interactions of A or B and T, are 
given by γA1 and γB1.  
 
Table 4 reports select coefficients from the difference-in-differences regressions that look at stock-out 
likelihood as the dependent outcome. The table first reports mean stock-out rates as assessed at endline. In 
contrast with the stock-out rates at baseline (Table 2) these mean values suggest substantially lower stock-
out incidence in both Model A and, especially, Model B facilities. For example, while the stock-out 
likelihood for AL 1x6 in control district facilities stood at 47.9%, only 29.2% of Model A districts and 
13.3% of Model B districts were out of the drug at time of survey – the baseline stock-out rates were 
much more similar in magnitude across the treatment and control arms. Table 4 also reports the exact 
standard error for the impact estimate coefficients in equation (1), namely γA1 and γB1.  
 
The likelihood of stock-outs is significantly lower in Model A facilities than control facilities for 6 of the 
15 tracer drugs – AL 2x6, AL 3x6, Amoxicillin, CTX, Depoprovera, and OralconF. Model B performed 
even more impressively – all but 3 of the 15 tracer drugs experienced significantly lower rates of stock-
out as a result of the Model B activities. Given the inferential challenges of the small number of districts 
in the study, the magnitude and precision of the gains are especially striking. The final column also 
presents the p-value for the difference-in-difference impact estimate comparing Models A and B directly. 
This shows that Model B also attains significantly lower stockouts when compared with Model A for 6 
drugs – all four forms of AL, Depoprovera, and SP – and nearly significant reductions for 3 additional 
drugs – Amoxicillin, OralconF, and Quinine. The number of significant or nearly significant findings for 
Model B along with greater reductions in mean stock-out rates indicates Model B performed relatively 
better than Model A in reducing the likelihood of stock-out. Given the aggregate nature of this systems 
intervention, the ability to identify statistically significant impacts under the conservative approach of 
Randomization Inference speaks to the magnitude of gains achieved but both models but, especially, 
Model B.  
 
A similar difference-in-difference analysis looking at drug inventory levels at time of survey is presented 
in Table 5 and the same general pattern is apparent – Model B performs significantly better than either 
fddXfdBfdAfdBfdAfd XTBTATBAO εγγγγγγγ +++++++= 111000  
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Model A or controls. Model B facilities hold significantly higher stocking levels for nine of the 15 tracer 
drugs when compared with controls, and 11 of 15 tracer drugs when compared with Model A. Taken 
together with the results on stock outs it is clear that Model B performs substantively better in terms of 
availability of drugs and inventory levels than either control or Model A districts for the majority of drugs 
studied. 
 
Another key measure of drug availability is the duration of stock-outs, measured here as the number of 
days a drug was unavailable over the common reference period of the fourth quarter of 2009. Figure 3 
shows the average number of days of stocks-outs of selected drugs in health facilities for the fourth 
quarter of 2009 across the different study arms (A, B, and control). Model B facilities experienced much 
reduced lengths of drug unavailability while A districts performed only marginally better than control 
districts. For pediatric AL 1x6, the drug was stocked out an average of 27 days out of a maximum of 92 
days in control districts while this number was 18 days in Model A facilities and 5 days in Model B 
facilities. A similar pattern occurs for AL 4x6 for adults, Amoxicillin, and CTX. Districts where Model A 
was implemented had more days of stock outs compared to comparison district for DepoProvera, and the 
difference between comparison districts (37 days) and A districts (36 days) for SP is negligible.  
 
A formal test of difference in stock-out duration can be conducted in a single difference regression 
framework given by equation (2):  
 
(2) 
 
where the outcome of interest, O, at facility f in district d is related to binary indicators for A and B 
districts, respectively. As before, the X vector controls for stratification variables. The coefficients of 
interest, those that identify the causal impact of Models A and B, are given by γA and γB. Table 6 conveys 
the mean number of days of stock-out for each of the 15 tracer drugs as well as the p-values for the 
regression coefficients γA and γB as well as a p-value of the formal direct test of Model A vs. Model B. In 
general, i.e. for 11 of the 15 tracer drugs, Model A experiences less drug stock-out days than control 
facilities. However for only one drug, AL 2x6, is this reduction significant. In contrast Model B yields far 
fewer days of drug stock-out for virtually all drugs (14 of the 15) and for 11 of these drugs the reductions 
are statistically significant. Model B facilities also experience significantly less stock-out days than Model 
A facilities for six of the tracer drugs. Overall, Model B results in significantly greater drug availability 
than either the existing distribution system in the control districts or that found in Model A  
 
Aside from the primary outcomes relating to the availability of drugs, the study assessed additional 
measures of supply chain effectiveness, notably pharmaceutical storage conditions at point of service. 
Table 7 lists 14 dimensions of storage conditions as judged by trained survey interviewers. The exact p-
values from regressions similar to the specification in equation (2) yield the precision of each pair-wise 
comparison. Select storage conditions are significantly higher at endline in both Models A and B than in 
the control facilities. Both Models A and B stock-rooms have significantly higher rates of separated 
damaged or expired medicines, appropriate fire safety equipment, and interviewer assessed adequate 
storage conditions. Model A stock-rooms also score significantly higher on 4 additional conditions and 
Model B scores higher on two further conditions. Comparing A and B directly, Model B facilities exhibit 
significantly higher rates of commodities stored and organized according to FEFO principles, storage kept 
fddXfdBfdAfd XBAO εγγγγ ++++= 0  
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at appropriate temperature, appropriate fire safety, and products stored on pallets and shelves. It is clear 
that the presence of CPs introduced in both models resulted in not only increased drug availability 
(especially in Model B districts) but also safer drug storage conditions. 
 
In conclusion, Models A and, especially, B were effective in increasing drug availability and storage 
conditions when compared to the “business-as-usual” distribution system. Presumably these gains in 
pharmaceutical availability will also impact population health for the better, although this dimension of 
impact was not assessed in the available data. An exercise in Appendix I attempts to translate these 
increases in tracer drug availability to improvements in health using both data from the randomized 
evaluation along with available published data on treatment seeking for malaria. This analysis posits a 
nationwide scale-up of Model B and suggests substantial health gains even when the benefits are 
restricted to this one disease. 
 
Discussion of Results 
 
While the previous analysis clear demonstrates the effectiveness of the two interventions, especially 
Model B, it has not yet highlighted the casual mechanisms behind the improved performance.  
 
Based on intuition one would argue that Model A would function better compared to Model B for drugs 
with higher demand variability. In Model A the district stores hold some “un-allocated” stock from which 
any unanticipated demand at the health facility level can be met. In Model B the district does not hold any 
stock and only has pre-packs earmarked for health facilities based on the quantities they ordered. If a 
health facility under-orders and then runs out of stock during the month, they would have to obtain supply 
all the way from MSL. Similarly, it appears that for items with lower demand variability Model B would 
function better because it reduces the health facility’s risk of stocking on account of poor ordering and 
allocation practices followed at the district i.e. if the district did not order the right quantities from MSL to 
fulfill health facility demand. Which of these factors will supersede the other depends on many behavioral 
and health systems aspects. 
 
The results from this evaluation indicate that availability at the health facility is higher under Model B as 
compared to Model A for almost all the drugs including those with high demand variability such as 
malaria medicines and those with low demand variability such as condoms. We argue that health facilities 
ordering directly from MSL with help from the Commodity Planner at the district can reasonably estimate 
the quantity they need to order for each month and this direct flow of demand information from the health 
facility to MSL is a key performance enhancing attribute of Model B. In Model A on the other hand (and 
also in the control districts), the demand at the health facility level is opaque both to MSL and often also 
to the district due to “order inflation” by the health facilities. Health facilities, knowing that district 
“rations” stock to them, tend to over order and the district loses its ability to robustly estimate the overall 
demand for the health facilities it serves in order to maintain the right amount of inventory. This leads to 
higher stock outs in Model A and in the control districts compared to Model B districts. Such behavior is 
witnessed in a number of industries, including consumer packaged goods and hi-tech electronics (Sterman 
2000) and its existence is attributed to both operational (Lee et al. 1997) and behavioral factors (Croson 
and Donohue 2006). A system where stock levels for many drugs have to be maintained at the district to 
serve the demand for multiple health facilities under a district faces multiple behavioral challenges such 
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as the cognitive limitation of the district level decision maker to manage the underlying complexity, the 
tendency of the health facility and district not to fully account for what is on-order but still not delivered 
when making ordering decisions (Sterman 1989), and the tendency to mistrust and develop counteracting 
strategies for the actions of decision makers at the higher (or lower) tier in the supply chain (Croson et al. 
2004). This randomized pilot allows us to understand the combined impact in our setting of these intricate 
operational and behavioral issues which are difficult to model analytical or through simulation. 
 
Both Model A and B perform better than the control districts because information flow and stock 
visibility are higher in Models A and B due to the presence of clear incentives for reporting. Figure 5 
underscores reporting compliance from CPs in both models where, in a matter of months, reporting 
achieved almost universal compliance. Linking ordering and information reporting as a requirement for 
receiving drug supplies incentivized health workers to report and order on a timely basis. As a result 
increased reporting rates were found in both Model A and Model B districts. The higher reporting rates in 
turn contributed to better visibility of health facility level demand at MSL leading to better planning and 
lower stock-outs. 
 
 The direct ordering from Health Facilities to a well-managed Logistics Management Unit based at MSL 
was also an important factor in the performance of Model B. There is reduced fragmentation and less 
possibility for communication errors. The well-trained logistics staff at MSL is dedicated to logistics 
management and provided improved supervision and management. In the current logistic system, the 
district health management teams have many competing tasks and responsibilities and not the same level 
of logistic capacity. Sealed packaging for the health facilities is likely to have made a difference in 
ensuring leakage in the supply chain during transportation and temporary storage is reduced. It also 
prevents district managers from making drug allocation decisions based on most immediate and visible 
needs in the system (District Hospital) without a full overview of the district wide demand for drugs.  
 
In both Model A and B district a commodity planner was recruited and trained as a dedicated logistics 
officer. The results of the study suggest that the role of the commodity planner alone was not the 
determining factor in the success of the study, although it could have possibly contributed to some of the 
improvements seen between the current system and model A.  
 
Future research 
 
This is the first large scale study to understand how to structure the public sector supply chain for 
distribution of essential medicines in low income countries. While this pilot and paper rigorously address 
the question of how to best structurally organize an essential drugs supply chain, it does not analyze 
operational issues such as the optimal inventory control policy at each level in the system. An analysis of 
health facility stock cards that was made possible through the pilot program shows that further 
improvements in availability of essential drugs at the health facility level are possible if a better inventory 
control system is run across supply chain (Gallien, Leung and Yadav 2011). Under the current system 
each health facility relies on the average monthly consumption of drugs over the past three months in 
computing its order quantity for the next month. This leads to stock outs for products with highly seasonal 
demand such as malaria drugs. Similarly, the current system fails to systematically anticipate any 
upcoming predictable changes in delivery lead-times and relies on a rather ad-hoc and subjective way for 
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allocating stocks to health facilities when inventory levels at MSL are not sufficient to cover all orders. 
Understanding the role of better inventory control systems and how they impact each supply chain 
structure requires further research, some of which is ongoing. 
 
  
15 
 
 
References 
Ballou, R. H. "Business Logistics Management: planning, organizing and controlling the supply chain", 
4th ed., Upper Saddle River, NJ : Prentice Hall, (1998). 
Bate R., K. Hess, L. Mooney 2010. Antimalarial Medicine Diversion Stock-Outs and Other Public Health 
Problems,  Research and Reports in Tropical Medicine , September 02, 2010 
Beer, K. (2007), “Zambia Malaria Commodity Security Assessment”, unpublished report to the World 
Bank. 
Bossert T. J, D M Bowserand J K Amenyah 2006. Is decentralization good for logistics systems? 
Evidence on essential medicine logistics in Ghana and Guatemala, Health Policy and Planning 22 (2). 73-
82. 
Cameron, A. C., Gelbach, J. B., & Miller, D. L. (2008). Bootstrap-based improvements for inference with 
clustered errors. The Review of Economics and Statistics, 90(3), 414-427. 
Clark, A. and H. Scarf. 1960. Optimal Policies for a Multi-echelon Inventory Problem. Management 
Science. 6. 475-490 
Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C, Mohamed AD, Miti SK, 
Campbell CC. Scaling up malaria control in Zambia: progress and impact 2005-2008. Am J Trop Med 
Hyg. 2010 Sep;83(3):480-8  
Chopra S , Meindl P (2007), Supply Chain Management: Strategy, Planning and Operation, 2nd Edition, 
New Jersey: Pearson Prentice Hall.  
Conn CP, Jenkins P, Touray SO. Strengthening health management: experience of district teams in the 
Gambia. Health Policy and Planning 1996;11:64-71.  
Croson R, K Donohue Behavioral causes of the bullwhip effect and the observed value of inventory 
information. - Management Science 2006 
Croson, R. T., Donohue, K. L., Katok, E., & Sterman, J. (2004). Order stability in supply chains: 
Coordination risk and the role of coordination stock. MIT Sloan School, Working Paper 2004 
Ernst, M. D. (2004). Permutation methods: a basis for exact inference. Statistical Science, 19(4), 676-685. 
Fletcher C., C.J. Wehlage, Multi-Tier Distribution Channels: Moving From Three Tier to Two Tier, 
Wednesday, December 17, 2008 , AMR Technical report 
Leung Z, Chen A, P Yadav, Gallien J, The Impact of Inventory Management on Stock-outs of Essential 
Drugs in Sub-Saharan Africa: Secondary Analysis of a Field Experiment in Zambia. LBS Working Paper 
2014 
Gue, K R. (2007), "Warehouse without Inventory," International Commerce Review, Vol. 7, No. 2, pp. 
124-132. 
Institute for Health Metrics and Evaluation. Financing Global Health 2013:Transition in an Age of 
Austerity. Seattle, WA: IHME, 2014. 
JSI and USAID | DELIVER PROJECT, Task Order 1. 2010. Emerging Trends in Supply Chain 
Management: Outsourcing Public Health Logistics in Developing Countries. Arlington, Va.: USAID | 
DELIVER PROJECT, Task Order 1. 
Lee, H. L. and Whang, S.(1999).Decentralized multi-echelon supply chain: incentives and information. 
Management Science, 45(5), pp. 633-640.  
16 
 
Lee, H. L., Padmanabhan, V. and Whang, S.(1997).Information distortion in a supply chain: the bullwhip 
effect. Management Science, 43, pp.546-558.  
Matowe L, Waako P, Adome RO, Kibwage I, Minzi O, Bienvenu E.A strategy to improve skills in 
pharmaceutical supply management in East Africa: the regional technical resource collaboration for 
pharmaceutical management. Hum Resour Health. 2008 Dec 23;6:30. 
Picazo, O and F. Zhao (2008). Zambia Health Sector Public Expenditure Review. Washington, DC: The 
World Bank Group. 
Quick, J. D., J. R. Rankin, R. O. Laing, R. W. O’Connor, H. V. Hogerzeil, M. N. G. Dukes, and A. 
Garnett, eds. 1997. Managing Drug Supply. 2nd ed. Management Sciences for Health.West Hartford, CT: 
Kumarian Press. 
Seiter, Andreas. A practical approach to pharmaceutical policy. World Bank Publications, 2010. 
Simchi-Levi, D., Kaminsky, P. and Simchi-Levi, E. (2003).Designing and Managing the Supply Chain: 
Concepts, Strategies and Case Studies. New York: McGraw-Hill.  
Sterman, J. (2000) Business Dynamics: Systems Thinking and Modeling for a Complex World. Boston: 
Irwin/McGraw-Hill. 
Sterman, J. (1989a) Modeling managerial behavior: Misperceptions of feedback in a dynamic decision 
making experiment, Management Science 35(3), 321-339. 
Yadav P, H Tata , M. Babaley (2011) Storage and Supply Chain Management. The World Medicines 
Situation 2011, Geneva WHO 
Yadav P, Focus on In-Country Supply Chains. Global Health Magazine, 2010 
Yadav P. Analysis of the public, private and mission sector supply chains for essential drugs in Zambia (a 
study conducted for DFID Health Resource Center under the aegis of the META project), 2007. 
http://apps.who.int/medicinedocs/en/d/Js18001en/  
Waako PJ, Odoi-adome R, Obua C, Owino E, Tumwikirize W, Ogwal-Okeng J, Anokbonggo WW, 
Matowe L, Aupont O. Existing capacity to manage pharmaceuticals and related commodities in East 
Africa: an assessment with specific reference to antiretroviral therapy. Hum Resour Health. 2009 Mar 
9;7:21. 
Waller, M A., C. R Cassady, and J Ozment (2006), "Impact of Cross-docking on Inventory in a 
Decentralized Retail Supply Chain," Transportation Research. Part E, Logistics & Transportation 
Review, Vol. 42, No. 5, pp. 359-382. 
World Health Organization (2004) The World Medicines Situation, Geneva WHO, 2004 chapter 7. 
World Bank (2015). Zambia country overview available at:  
http://www.worldbank.org/en/country/zambia/overview 
Zinn W, DJ Bowersox. Planning physical distribution with the principle of postponement. Journal of 
Business Logistics 9 (2) . 1988
17 
 
 
Table 1. Description of the three distribution models  
Model Characteristics Model A Model B Control 
Commodity Planner 
coordinates logistics at 
district level 
Yes  Yes  No 
Storage of drugs at 
district level 
Yes No  Yes 
Entity where health 
facilities submit their 
orders 
District Store (then an 
aggregate order for the 
district is submitted to 
MSL) 
Directly to MSL District Store (then an 
aggregate order for the 
district is submitted to 
MSL) 
Number of tiers in the 
system 
3 2 3 
Sealed individual 
packages to health 
facilities are assembled 
at MSL 
No Yes No 
Intended frequency of 
delivery from MSL to 
districts 
Monthly Monthly Monthly 
Intended frequency of 
delivery from district 
store to health facilities  
Monthly to facilities 
with adequate storage 
space otherwise bi-
monthly 
Monthly to facilities 
with adequate storage 
space otherwise bi-
monthly 
Monthly to facilities 
with adequate storage 
space otherwise bi-
monthly 
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Table 2. Probability of stock-out in health centers and health posts at time of baseline interview, by tracer drug 
 
Tracer drug Control (K) mean 
Model A 
mean 
Exact P-
value: A 
vs. K 
Model B 
mean 
Exact P-
value: B 
vs. K 
Exact P-
value: B vs. 
A 
AL 1x6 (strip of 6 tabs) 0.423 0.338 0.113 0.433 0.923 0.596 
AL 2x6 (strip of 12 tabs) 0.380 0.462 0.133 0.550 0.725 0.902 
AL 3x6 (strip of 18 tabs) 0.338 0.431 0.049 0.483 0.904 0.713 
AL 4x6 (strip of 24 tabs) 0.338 0.400 0.893 0.400 0.734 0.286 
Amoxicillin Suspension (bottle of 100ml) 0.718 0.738 0.826 0.717 0.730 0.689 
Benzyl Penicillin Inj. (5ML 10ml vials) 0.225 0.246 0.306 0.200 0.644 0.340 
CTX 480mg (bottle of 1000 tabs) 0.451 0.415 0.379 0.400 0.352 0.038 
DepoProvera (vial) 0.254 0.385 0.169 0.450 0.812 0.233 
Malaria RDTs (box of 25 tests) 0.465 0.462 0.599 0.433 0.513 0.375 
Male Condoms (box of 100/144) 0.183 0.262 0.506 0.317 0.900 0.166 
Metronidazole 200mg tabs (bottle of 1000) 0.606 0.615 0.502 0.533 0.804 0.188 
OralconF (Levonorgestre/Ethinylestradio) 0.408 0.585 0.585 0.700 0.155 0.021 
Quinine Injection (2ml ampoules) 0.338 0.477 0.157 0.467 0.629 0.701 
Quinine Tabs (bottle of 1000 tabs) 0.085 0.031 0.114 0.183 0.809 0.250 
SP (bottle of 1000 tabs) 0.535 0.585 0.413 0.517 0.806 0.492 
       Note: Estimates based on data from 196 facilities in 24 districts. Exact p-values calculated through randomization inference. P-values in bold significant 
at 10% level in a two-tailed hypothesis test. 
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Table 3. Inventory count in health centers and health posts at time of baseline interview, by tracer drug 
 
Tracer drug Control (K) mean 
Model A 
mean 
Exact P-
value: A 
vs. K 
Model B 
mean 
Exact P-
value: B 
vs. K 
Exact P-
value: B vs. 
A 
AL 1x6 (strip of 6 tabs) 48.72 38.95 0.355 46.33 0.316 0.596 
AL 2x6 (strip of 12 tabs) 34.80 36.51 0.358 32.65 0.177 0.676 
AL 3x6 (strip of 18 tabs) 48.57 47.00 0.039 45.22 0.514 0.084 
AL 4x6 (strip of 24 tabs) 39.45 54.72 0.174 35.35 0.089 0.085 
Amoxicillin Suspension (bottle of 100ml) 1.61 6.51 0.691 2.87 0.733 0.012 
Benzyl Penicillin Inj. (5ML 10ml vials) 27.18 32.91 0.234 23.18 0.158 0.097 
CTX 480mg (bottle of 1000 tabs) 1.88 1.58 0.339 3.04 0.323 0.261 
DepoProvera (vial) 55.35 33.11 0.196 35.28 0.181 0.563 
Malaria RDTs (box of 25 tests) 4.10 18.06 0.590 4.80 0.154 0.794 
Male Condoms (box of 100/144) 13.99 8.11 0.790 8.58 0.436 0.635 
Metronidazole 200mg tabs (bottle of 1000) 0.63 0.98 0.454 0.97 0.399 0.691 
OralconF (Levonorgestre/Ethinylestradio) 118.93 40.17 0.396 36.32 0.167 0.051 
Quinine Injection (2ml ampoules) 73.57 55.65 0.057 21.58 0.118 0.034 
Quinine Tabs (bottle of 1000 tabs) 2.24 3.95 0.405 2.65 0.458 0.422 
SP (bottle of 1000 tabs) 0.59 0.62 0.823 0.63 0.201 0.500 
       Note: Estimates based on data from 196 facilities in 24 districts. Exact p-values calculated through randomization inference. P-values in bold significant at 
10% level in a two-tailed hypothesis test. 
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Table 4. Difference-in-difference estimate of probability of stock-out, by tracer drug 
   
Tracer drug 
Control 
(K) 
endline 
mean 
Model A 
endline 
mean 
Exact P-
value of dif-
n-dif 
coefficient: 
A vs. K 
Model B 
mean 
Exact P-
value of dif-
n-dif 
coefficient: B 
vs. K 
Exact P-
value of dif-
n-dif 
coefficient: B 
vs. A 
AL 1x6 (strip of 6 tabs) 0.479 0.292 0.161 0.133 0.015 0.037 
AL 2x6 (strip of 12 tabs) 0.417 0.246 0.043 0.083 0.002 0.037 
AL 3x6 (strip of 18 tabs) 0.493 0.231 0.007 0.050 0.000 0.031 
AL 4x6 (strip of 24 tabs) 0.557 0.400 0.118 0.117 0.009 0.026 
Amoxicillin Suspension (bottle of 100ml) 0.521 0.323 0.072 0.167 0.023 0.124 
Benzyl Penicillin Inj. (5ML 10ml vials) 0.028 0.031 0.449 0.033 0.572 0.768 
CTX 480mg (bottle of 1000 tabs) 0.732 0.400 0.034 0.350 0.034 0.414 
DepoProvera (vial) 0.408 0.185 0.026 0.000 0.002 0.085 
Malaria RDTs (box of 25 tests) 0.380 0.185 0.127 0.183 0.217 0.559 
Male Condoms (box of 100/144) 0.113 0.123 0.243 0.067 0.031 0.161 
Metronidazole 200mg tabs (bottle of 1000) 0.437 0.462 0.544 0.417 0.646 0.615 
OralconF (Levonorgestre/Ethinylestradio) 0.324 0.154 0.065 0.067 0.008 0.103 
Quinine Injection (2ml ampoules) 0.183 0.169 0.147 0.033 0.051 0.165 
Quinine Tabs (bottle of 1000 tabs) 0.211 0.077 0.246 0.117 0.073 0.106 
SP (bottle of 1000 tabs) 0.606 0.484 0.179 0.167 0.027 0.090 
       Note: Estimates based on data from 196 facilities in 24 districts. Regression specification includes stratification variables (rural or peri-urban, 
region, and high-risk stock out indicator). Exact p-values calculated through randomization inference. P-values in bold significant at 10% level in a 
one-tailed hypothesis test. 
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Table 5. Difference-in-difference estimate of inventory counts, by tracer drug 
   
Tracer drug 
Control 
(K) 
endline 
mean 
Model A 
endline 
mean 
Exact P-
value of dif-
n-dif 
coefficient: 
A vs. K 
Model B 
mean 
Exact P-
value of dif-
n-dif 
coefficient: B 
vs. K 
Exact P-
value of dif-
n-dif 
coefficient: B 
vs. A 
AL 1x6 (strip of 6 tabs) 69.28 76.56 0.363 139.50 0.052 0.021 
AL 2x6 (strip of 12 tabs) 97.68 81.86 0.570 177.93 0.068 0.001 
AL 3x6 (strip of 18 tabs) 89.93 72.97 0.566 152.67 0.125 0.003 
AL 4x6 (strip of 24 tabs) 62.60 56.30 0.617 161.33 0.044 0.002 
Amoxicillin Suspension (bottle of 100ml) 9.00 19.31 0.130 68.47 0.001 0.001 
Benzyl Penicillin Inj. (5ML 10ml vials) 48.56 31.55 0.925 58.03 0.193 0.004 
CTX 480mg (bottle of 1000 tabs) 1.45 3.10 0.115 4.59 0.173 0.494 
DepoProvera (vial) 46.19 93.66 0.044 262.45 0.000 0.002 
Malaria RDTs (box of 25 tests) 14.03 7.84 0.997 9.63 0.577 0.005 
Male Condoms (box of 100/144) 28.51 12.05 0.777 28.19 0.362 0.033 
Metronidazole 200mg tabs (bottle of 1000) 1.22 2.39 0.139 2.28 0.082 0.551 
OralconF (Levonorgestre/Ethinylestradio) 144.94 390.82 0.102 269.55 0.100 0.621 
Quinine Injection (2ml ampoules) 76.53 37.03 0.641 157.95 0.000 0.000 
Quinine Tabs (bottle of 1000 tabs) 50.69 3.52 0.703 5.49 0.593 0.118 
SP (bottle of 1000 tabs) 0.48 0.73 0.229 2.06 0.002 0.004 
       Note: Estimates based on data from 196 facilities in 24 districts. Regression specification includes stratification variables (rural or peri-urban, 
region, and high-risk stock out indicator). Exact p-values calculated through randomization inference. P-values in bold significant at 10% level in a 
one-tailed hypothesis test. 
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Table 6. Total days of stock-out in the 4th quarter 2009, by tracer drug 
    
Tracer drug Control (K) mean 
Model A 
mean 
Exact P-
value: A vs. 
K 
Model B 
mean 
Exact P-
value: B vs. 
K 
Exact P-
value: B vs. 
A 
AL 1x6 (strip of 6 tabs) 27.3 17.9 0.268 4.9 0.030 0.044 
AL 2x6 (strip of 12 tabs) 15.2 12.2 0.069 0.3 0.073 0.165 
AL 3x6 (strip of 18 tabs) 18.5 16.2 0.920 2.3 0.370 0.129 
AL 4x6 (strip of 24 tabs) 23.7 13.6 0.391 1.2 0.079 0.020 
Amoxicillin Suspension (bottle of 100ml) 27.4 21.3 0.368 8.0 0.105 0.137 
Benzyl Penicillin Inj. (5ML 10ml vials) 3.2 3.7 0.143 1.9 0.011 0.068 
CTX 480mg (bottle of 1000 tabs) 35.2 33.3 0.349 23.2 0.016 0.436 
DepoProvera (vial) 10.6 15.3 0.160 3.6 0.084 0.097 
Malaria RDTs (box of 25 tests) 12.4 11.7 0.541 9.1 0.054 0.114 
Male Condoms (box of 100/144) 9.5 7.7 0.161 4.4 0.148 0.737 
Metronidazole 200mg tabs (bottle of 1000) 31.7 34.5 0.561 32.3 0.166 0.385 
OralconF (Levonorgestre/Ethinylestradio) 10.2 13.6 0.486 22.5 0.008 0.553 
Quinine Injection (2ml ampoules) 4.2 3.6 0.363 0.0 0.013 0.093 
Quinine Tabs (bottle of 1000 tabs) 5.4 5.1 0.855 3.2 0.012 0.085 
SP (bottle of 1000 tabs) 37.4 35.9 0.915 14.1 0.059 0.315 
       Note: Estimates based on data from 196 facilities in 24 districts. Regression specification includes stratification variables (rural or peri-urban, 
region, and high-risk stock out indicator). Exact p-values calculated through randomization inference. P-values in bold significant at 10% level in a 
one-tailed hypothesis test. 
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Table 7. Likelihood of satisfying select storage conditions observed at time of interview 
   
Storage condition Control (K) mean 
Model A 
mean 
Exact P-
value: A 
vs. K 
Model B 
mean 
Exact P-
value: B vs. 
K 
Exact P-
value: B vs. 
A 
Commodities stored and organized according to FEFO 0.59 0.75 0.163 0.85 0.008 0.013 
Separated damaged or expired medicines 0.77 0.96 0.011 0.94 0.010 0.331 
Medicines separated from insecticides and chemicals 0.82 0.92 0.098 0.91 0.104 0.418 
Sufficient current storage space 0.62 0.64 0.306 0.66 0.354 0.408 
Storage area free of rodents or insects 0.66 0.77 0.114 0.67 0.425 0.384 
Storage secured by lock and key 0.95 0.95 0.481 1.00 0.031 0.116 
Protection from direct sunlight 0.91 0.97 0.065 0.93 0.485 0.995 
Storage area kept at appropriate temperature 0.74 0.67 0.826 0.73 0.626 0.017 
Supplies protected from water penetration 0.82 0.77 0.768 0.90 0.178 0.138 
Appropriate fire safety equipment 0.23 0.48 0.043 0.51 0.014 0.040 
Products stored on pallets/shelves 0.74 0.78 0.448 0.87 0.137 0.039 
Products stored away from outer wall 0.55 0.67 0.095 0.55 0.448 0.856 
Interviewer assessed adequate storage conditions 0.59 0.77 0.055 0.78 0.052 0.216 
Interviewer assessed facility maximized storage potential 0.73 0.88 0.021 0.75 0.550 0.943 
       Note: Estimates based on data from 196 facilities in 24 districts. Regression specification includes stratification variables (rural or peri-urban, region, 
and high-risk stock out indicator). Exact p-values calculated through randomization inference. P-values in bold significant at 10% level in a one-tailed 
hypothesis test. 
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Figure 1. Participating study districts by treatment arm 
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Figure 2: Comparison of baseline and endline stock-out rates in model A district health facilities, select 
tracer drugs 
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Figure 3: Comparison of baseline and endline stock-out rates in model B district health facilities, select 
tracer drugs 
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Figure 4: Number of days of stock outs in Q4 2009 of select tracer drugs by treatment arm 
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Figure 5: Average reporting rate to MSL by A and B districts by month of implementation 
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Appendix 1 – Comparative effectiveness and cost-effectiveness of the supply-chain interventions  
 
The evaluation directly measures the gains in drug availability as a result of the supply-chain 
interventions. Translating these increases in availability to gains in health – an important step necessary to 
compare the effectiveness of these interventions in relation to other potential uses of health resources – 
requires a modeling exercise that leverages household survey estimates of health behavior as well as 
epidemiological estimates of disease burden. 
 
There is no standard methodology for estimating the health outcome impact of stock-outs. The key health 
outcome investigated in this exercise is malaria-related mortality and a decision tree framework was used 
to estimate the impact on mortality and morbidity of reduced stock-outs rates of the first-line malaria 
treatment in A, B and comparison districts. A patient centered decision-tree framework was adopted to 
describe the decision alternatives that may be chosen by a patient/care giver who encounters a stock out in 
a public health facility. The consequences for each pathway the patient can take in terms of full recovery, 
partial recovery, deaths, and days of illness were then measured. Appendix 2 presents the full decision 
tree framework for both under-five and over-five malaria infections. 
 
The estimates presented focus only on the health outcome improvements from a reduction in the stock 
outs of Artemether Lumefantrine (AL) used for the treatment of uncomplicated malaria.11 Because the 
pilot program had a positive impact on the access to all essential drugs that are supplied to the health 
facilities, these estimated health gains are highly conservative in their focus on one drug – there is no 
additional attempt to estimate health gains from increased availability of the 52 medicines and medical 
supplies in the Primary Health Center (PHC) Kit and over 50 other medicines in various pack forms that 
are available in the MSL catalogue and are ordered by health facilities.  
 
Under Model B the probability that not one of the ACT packages is available at a given clinic is only 1 
percent. Given that stock-outs are substantially higher in Model A and control districts, the health gains 
should be significant. This decision-tree approach deliberately takes conservative estimates of key 
behavioral parameters. The results suggest that if Model B were scaled-up nationwide, under-five and 
over-five mortality due to malaria would decrease by 21 percent and 25 percent respectively. Appendix 
Table 1 presents a comparison of the current system (the control), Model A and Model B in terms of 
actual cases of uncured malaria, severe malaria, and deaths due to malaria for under-five and over-five 
children respectively should these different models be scaled up nationwide. Translating the information 
in the table to averted deaths, if Model B were scaled up nationwide, an additional 3,320 under-five 
deaths and 448 over-five deaths due to malaria would be averted each year. This implies a reduction of 
21.4 percent and 25.4 percent in under-five and over-five mortality attributable to malaria respectively.  
 
                                                          
11 We assume full substitutability between the 4 different weight bands for Artemether Lumefantrine for under-five 
patients implying that a health facility will dispense fewer tablets from a strip of 24 , 18 or 12 tabs rather than not 
fulfilling the demand for a strip of 6 for a children less than five years old. Admittedly, some health facilities may 
not engage in such a practice but this assumption allows us to obtain the most conservative estimates for the 
reduction in mortality and morbidity. 
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An episode of illness also has a significant economic cost to the household due to the productive time lost 
per episode for a sick adult and also for an adult caring for sick children. Often times, the economic 
burden of an illness episode on a household can be devastating enough to bring a household into extreme 
poverty, debt and the sale of assets, which jeopardizes a household’s future earnings potential. Again with 
a focus on untreated or ineffectively treated malaria, and using the concept of foregone income (i.e. 
calculating the value of lost workdays as a result of malaria based on estimated wages) a national scale-up 
of model B should result average direct savings of over $ 1,629,312.12 Appendix Table 2 summarizes the 
benefit from national scale-up of Model.  
 
Although Models A and B are effective to various degrees, another important consideration for health 
policy makers is the relative cost of each option. A comprehensive costing exercise covered both 
recurrent costs such as salaries and transport as well as fixed initial costs such as staff recruitment and 
training. In order to estimate a per district average monthly cost the fixed initial cost was distributed over 
a 5 year period. As costs will be compared across versions A, B, and control areas, future costs were 
neither adjusted for expected inflation nor were they discounted (this is equivalent to setting the discount 
rate to equal the expected inflation rate). All costs were measured in 2010 Zambian Kwacha and cost 
aggregates then converted to US dollars at the 2010 exchange rate of 4500 Kwacha to one dollar. 
 
The estimated additional costs to the supply chain per district per month are presented in Appendix Table 
3. These costs are estimated to be $3479 for intervention A and $3971 for B (including recurrent costs 
and fixed costs). The monthly recurrent costs for Model A and Model B are $2832 and $3325 
respectively. The cost difference between the two interventions is due to the additional transport costs 
captured under B as well as higher personnel costs at central stores for picking and packing activities. The 
estimate cost differential implies that the additional cost of B is 17 percent greater than the additional cost 
of A. Given the relative performance of version B, this cost differential may well be worth the investment. 
 
When comparing the average distribution cost in pilot areas to the equivalent for the average district in 
Zambia, it is important to keep in mind that the pilot was implemented in remote districts with higher 
transportation costs. In many ways the more pertinent cost comparison is with regards to the per district 
monthly cost of the existing distribution system. This cost, determined by dividing the total system cost 
by the number of districts in Zambia, is $3878.13 This cost estimate includes the distribution of all drugs, 
not only essential medicines, although essential medicines make up the vast majority of staff time, storage 
space, picking activity, and transport volumes. This estimate is the average for all districts in Zambia, 
including centrally located and relatively accessible districts, where the average cost is undoubtedly lower 
due to lower transport costs. Hence a comparison of the additional costs of A or B, which have been 
measured in the more remote districts of Zambia, against the distributional costs in an average Zambian 
district may somewhat overstate the cost differential and this should be born in mind when comparing the 
relative costs of various delivery options. 
                                                          
12 We assume the average additional time lost per episode of malaria that is not effectively treated to be 2 days for a 
sick adult and also 2 days for an adult caring for sick children. Admittedly, apart from the direct short term 
economic consequences due to wages lost, there are also likely to be significant indirect effects and long term effects 
such as income lost due to death/increased mortality and cognitive loss due to malaria related anemia in young 
children. The estimation of such long term consequences of treating a larger fraction of the population with effective 
drugs is beyond the scope of this study. 
13 This value is estimated based on 2010 MOH salaries.  
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How do these intervention costs relate to the gains observed by models A and B? Cost-effectiveness 
interventions of the two models are presented in two ways – first in terms of the cost per day of essential 
medicine stock-out averted (weighting all tracer drugs equally) and then in terms of cost per Year of Life 
Lost (YLL) averted as a result of the increased availability of one essential anti-malarial drug, AL. To 
estimate the cost per stock-out day averted, assume a district of average size with 18 health facilities. The 
evaluation results suggest that in the fourth quarter of 2009 there was an average of 1704 stock-out days 
per month across all 15 tracer drugs in the control districts. This total reduces to 1464 in Model A and 756 
in Model B. Thus by this metric, Model A reduces a stock-out day of one tracer drug at a cost of $14.5 in 
additional operating costs. Model B, on the other hand, achieves the same stock-out reduction at a cost of 
$4.2. With regards to this particular measure of stock availability, Model B is three and a half times as 
cost-effective as Model A. 
 
To express cost-effectiveness in terms of health gains, focus on malaria deaths averted due to increase 
availability of ACT at the facility level. As expressed earlier, a national scale-up of Model B may result in 
3320 fewer under-five deaths and 448 over-five deaths annually. In 2008, the life expectancy in Zambia 
(World Bank WDI, 2008) was estimated at 45.4 years. In terms of years of life lost averted, this translates 
into 720,440 YLLs averted from the reduction in under-five deaths, and 50,175 from the reduction in over 
five deaths (assuming the median age of Zambians over 5 is 22 years as per the 2011 CIA World 
Factbook). This implies a monetary value of $22 per YLL averted for a national scale-up of Version B 
operating over a 5 year period. 
 
In addition, the cost estimates above do not take into account possible savings such as the discontinuation 
of picking and packing services at the district level, or the saved local transport costs from the district 
store to the facility. A scale-up may also involve further savings such as the ability to reassign the district-
level store keeper to other duties as that position is no longer necessary. By inclduing these savings, the 
net additional monthly operating costs of Model B falls to a maximum of $2992 and perhaps even less 
depending on the current transport costs incurred at the district level. If these additional savings are 
included in the analysis the additional cost for Model B will less and hence the cost-effectiveness 
estimates even greater. 
 
It is difficult to find benchmark comparisons for this estimate of cost-effectiveness since it is a marginal 
investment into an active health system. However one contextual comparison is the estimated cost-
effectiveness of antiretroviral therapy where one estimate for Sub-Saharan Africa stands at $350/DALY 
averted (Marseille et al. 2002).14 This comparison cost-effectiveness includes additional inputs such as 
medical staff as well as pharmaceutical costs. Other benchmarks include the cost-effectiveness of a global 
ACT subsidy at approximately $43/YLL averted (assuming full subsidy of one dollar per treatment course 
of ACT and the life expectancy for Zambia) (Laxminarayan et al. 2006) and the cost effectiveness of 
intermittent preventive treatment for malaria in pregnant women with Sulfadoxine-Pyrimethamine (SP) of 
$19/DALY averted (Yadav, 2010). Whichever benchmark that is being used, it is clear from this analysis 
that investments in the supply chain are cost-effective compared to other common public health 
                                                          
14 In the case of malaria DALY and YLL are not equal but similar given that effects of malaria on disability are small. 
Correspondingly, the bulk of HIV related DALYs derive from YLLs. 
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interventions. In addition, this supply chain estimate only concerns malaria deaths averted and not the 
possible other numerous health benefits from increased availability of other essential drugs. 
 
While the additional cost of A or B is large in proportional terms – a national scale up of Model B would 
increase the supply chain operational cost from 4.1 percent to 8.5 percent of the total pharmaceutical 
budget in Zambia – the cost implications should be understood in light of international comparisons. 
Benchmarks of the distribution cost in relation to drug cost show that the equivalent number for less-
developed and geographically challenged states (e.g. Tanzania, Malawi and Rwanda) is between 20-25 
percent and for more developed states between 12-20 percent (USAID, 2009). The equivalent number for 
the ARV system in Zambia is about 10 percent in urban areas and 16 percent in rural areas (ibid). In 
general, logistics costs tend to decline with increased efficiency in the economy (e.g. improved 
infrastructure). Therefore distribution costs are generally higher in developing countries compared to 
developed countries. The current distribution cost of 4.1 percent in Zambia is even lower than typical 
logistic costs of US pharmaceutical companies which are around 4.5 percent (ibid). These data and the 
poor performance of the supply chain system suggest that Zambia is currently under-investing in its 
supply chain and the cost for scaling up Model B would still keep distribution costs below benchmarks in 
countries with similar level of development. 
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Appendix Table 1. Estimates of annual cases of uncured malaria cases, severe malaria cases and deaths 
by population groups for as-is (the current system), Option A and Option B (assuming nationwide 
coverage of each system) 
 
Under-five population Over-five population (1) 
  Control Option A Option B As-is Option B  
Uncured malaria cases 621,526 614,885 488,711 706,242 527,043  
Severe malaria cases 31,076 30,744 24,436 7,062 5,270  
Deaths 15,538 15,372 12,218 1,766 1,318  
Note: (1) Only the results of Option B are presented because in this case Option A leads to a slight 
increase in the probability of stock out as compared to the “as-is” case for adult bands of ACT. As before, 
this increase is however statistically insignificant and therefore not included in the table. 
 
 
 
Appendix Table 2. Annual benefits from national scale-up of Model B at-a-glance (compared to the 
current system) 
Reduction 
in 
uncured 
malaria 
cases per 
year 
Reduction 
in Severe 
malaria 
cases per 
year 
Under 
5 
Deaths 
averted 
per 
year 
Over 5 
Deaths 
averted 
per 
year 
 
Total 
deaths 
averted 
Aggregate 
average direct 
household 
income loss 
saved 
312,014 8,433 3,320 448 3758 $ 1,629,312 
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Appendix Table 3. Estimated district average monthly incremental costs ($) of Versions A and B, by cost category 
Cost category Model A Model B 
Recurrent cost - staff related 
  Salaries 1693 1867 
Travel Expenses by CPs, Project Manager, Supervisors etc to Piloted Districts  87 87 
Telephone/Cellphone Accessories and Expenses 106 106 
Staff Welfare expenses-Accomodation for CPs, Refreshments etc 90 90 
Group Life Assurance Premium 8 8 
Gratuities 476 537 
Medical Expenses 8 8 
Recurrent cost - other categories 
  Packaging Material for Repackaging of Drugs 8 33 
Fuel & Lubricants - Travel by Project Manager to Piloted Districts & Entitlements 33 33 
Extra fuel for distribution trips 78 311 
Canteen Expenses 96 96 
Stationery & office Supplies 87 87 
Bank Charges 14 14 
Postage 4 4 
Repairs & Maintenance General-Computers 44 44 
Fixed cost 
  Recruitment Expenses 11 11 
Subscription & Licenses (Medical Council of Zambia - Pharmacist CP's)  1 1 
Protective Clothing for Warehouse WBP Staff 0 0 
Computer & Computer Accessories 26 26 
Pallet Jacks for Warehouse 6 6 
Office Equipment-Aircon, Solar Panels etc 3 3 
Furniture,Fixture & Fittings 5 5 
Computer Software 7 7 
Training Materials 65 65 
District Personnel Training Costs 454 454 
Monitoring and Evaluation Costs 67 67 
Total           3,479            3,971  
Note: Exchange rate = 4500 Kwacha/dollar 
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Appendix 2 - The impact of reduced stock-outs of ACTs on under- and over-five mortality  
 
1,508,448 cases of malaria were reported amongst children less than 5 years old in Zambia in 2008 
(World Malaria report 2009). Of these, approximately 61.8 percent (LCMS 2006) sought any form of 
formal consultation for malaria like fevers. Approximately 28.6 percent self-administered medicines 
purchased primarily (95 percent) in non-public sites. Among those who sought formal consultation, 93 
percent seek care at a public sector facility and 62 percent of those who use drugs for the treatment of 
malaria like fevers obtain them in a public sector facility.  
 
The market share of ACTs in the non-public sector at the time of the intervention stands at 8.0 percent 
based on multiple earlier studies on the private anti-malarial market in Zambia. The remaining 92 percent 
of those who obtain drugs in the private sector use primarily SP (Fansidar).  
 
Chanda et al. (2007) suggests the current efficacy of AL is 98.2 percent as compared to 68.4 percent for 
SP. In accordance with the longer length of AL treatment relative to SP/Fansidar the compliance of ACTs 
is set at 75.2 percent and of SP at 85 percent. These figures are also from Chanda et al. (2007) but tie 
closely with other studies on malaria interventions notably (Saving Lives Buying Time, Arrow et al, IOM 
2004). A further assumption posits that 50 percent of patients who do not comply with the complete 
dosage of AL are still cured whereas non-compliance with SP full dosage leads to a 0 percent cure rate. 
These parameters are widely accepted in numerous cost-effectiveness studies on malaria treatment due to 
the shorter treatment course of SP and its mechanism of parasite elimination.  
 
Currently those who seek treatment in the control public facilities find any dosage form of AL available 
only 59 percent of the time. Upon encountering a stock out, the caregivers have to resort to seeking 
treatment in the non-public sector where the share of AL was extremely low at the time of study. In a 
fraction of cases (10 percent) these caregivers do not seek any formal treatment at all once they cannot 
find drugs in the public sector health facility. The result being that a larger number of care givers obtain 
ineffective SP treatment in the private sector. This translates into 621,526 of the total 1,508,448 under 
five malaria cases not being effectively treated. 5 percent of these ineffectively treated cases translate into 
severe malaria with a 50 percent chance of death resulting from it.  
 
One caveat is that those presenting for consultation at a public sector clinic and encountering a stock out 
might in some cases travel to other health facilities. However, given the acute nature of malaria symptoms 
for children under five and the lack of patient transport systems in most primary care health centers, such 
instances are assumed to be rare and thus not have a significant effect. Also, when stock outs occur, the 
duration is several days (average duration in the current as-is system is 22 days for all forms of AL) 
thereby not allowing repeat visits to the health facility. The decision and flow pathway which brought 
about the numbers quoted above are illustrated in Appendix Figure 1.  
 
The reduction in ineffectively treated cases, complicated cases and mortality for patients over five years 
or older is estimated using a similar approach as described above. The only significant difference in the 
computation is the proportion of those who seek any form of treatment is slightly lower for the over-five 
population. Also, a more stringent assumption of 30 percent of those over five years old who seek 
treatment in the public sector health facilities and encounter a drug stock out on the day of their visit do 
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not obtain any treatment at all. This fraction is higher as compared to the 10 percent for under-five. 
Multiple earlier studies have documented such behavior among adults with malaria. The higher developed 
immunity in the population over 5 leads to fewer cases of complicated malaria (1 percent) and fewer of 
the complicated cases resulting in death (25 percent) even when malaria was not treated effectively. 
Appendix Figure 2 depicts the decision and flow pathway for the over-five population.  
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Appendix Figure 1. A model of patient flow and treatment seeking to estimate the impact of stock-out 
reductions on the under-5 population 
 
  
1,508,448
u5 cases
61.8% 28.6% 9.6%
932,221 431,416 144,057
Seek formal consultation Self treat No treatment
93.12% 6.88% 95.03% 4.97%
868,084 64,137 409,975 21,441
public sector non public sector drugs obtained in non-public sector drugs obtained in public sector
59.0% 41.0%
512,170 355,914
find ACT do not find ACT
90% total non public sector
10% 794,435
35,591
seek no treatment 8.24% 91.76%
65,461 728,973
ACT SP+Others
Obtain ACTs 577,631
Obtain SP or other treatment
728,973
75.1% 24.9% 85.0% 15.0%
433,801 143,830 619,627 109,346
take full course partial course take full course partial course
1.8% 50% 40.8% 0%
7,808 71,915 252,808 109,346
Treatment ineffective Treatment ineffective Treatment ineffectivTreatment ineffective
Total of ineffective or no treatment 621,526
5%
Severe malaria 31,076
50%
Deaths from severe malaria 15,538
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Appendix Figure 2. A model of patient flow and treatment seeking to estimate the impact of stock-out 
reductions on the over-5 population
 
 
 
 
1,571,853
>5 cases
59.9% 30.1% 9.98%
941,854 473,128 156,871
Seek formal consultation Self treat No treatment
92.63% 7.37% 90.59% 9.41%
872,440 69,415 428,606 44,521
public sector non public sector drugs obtained in non-public sector drugs obtained in public sector
53.0% 47.0%
462,393 410,047
find ACT do not find ACT
70% total non public sector
30% 785,054
123,014
seek no treatment 8.24% 91.76%
64,688 720,365
ACT SP+Others
Obtain ACTs 527,081
Obtain SP or other treatment
720,365
75.1% 24.9% 85.0% 15.0%
395,838 131,243 612,311 108,055
take full course partial course take full course partial course
1.8% 50% 40.8% 0%
7,125 65,622 249,823 108,055
Treatment ineffective Treatment ineffective Treatment ineffectivTreatment ineffective
Total of ineffective or no treatment 710,509 706,242
1% 1%
Severe malaria 7,105 7,062
25% 25%
Deaths from severe malaria 1,776 1,766
